# RSM01, an extended half-life RSV monoclonal antibody with a high barrier to in vitro resistance

Source: [Medical research : nature.com subject feeds](https://www.nature.com/articles/s41467-026-79029-z) · 2026-11-17 · Medicine
Page: https://themorning.science/story/rsm01-an-extended-half-life-rsv-monoclonal-antibody-with-a-high-barrier-to-in-vi-02ca8a02df8b7452
Kind: research · Impact: low

## In brief

- Nature publishes a research article on RSM01, an RSV monoclonal antibody with an extended half-life.
- The source reports the antibody has a high barrier to in vitro resistance.
- The feed entry provides no summary, so further technical details are not available from the sources.

## Why it matters

An antibody with a longer half-life could mean less frequent dosing for protecting infants and adults against respiratory syncytial virus, though the sources only confirm the headline claims.

## Timeline

- 2026-11-17: Article listed in Nature subject feed

## Coverage

- [RSM01, an extended half-life RSV monoclonal antibody with a high barrier to in vitro resistance](https://www.nature.com/articles/s41467-026-79029-z) — Medical research : nature.com subject feeds, 2026-11-17

Tags: rsv, monoclonal antibody, antiviral resistance, immunology

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science
